Loading company…
Sensei Biotherapeutics develops immune therapies for cancer and infectious diseases.
Founded in 1999 and based in Maryland, Sensei Biotherapeutics develops immune therapies using its ImmunoPhage platform, which engineers non-infectious bacteriophages to display target antigens. Its pipeline includes SNS-301, SNS-401, and SNS-VISTA. The company filed an IPO prospectus in November 2020.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in